Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTIC NASDAQ:GNPX NASDAQ:NMTR NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/AGNPXGENPREX$0.28-2.4%$0.28$0.20▼$3.97$9.42M-0.54.16 million shs152,198 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs1,648 shsPRQRProQR Therapeutics$2.36+0.0%$1.84$1.07▼$4.62$246.72M0.36657,396 shs47,463 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTICCTI BioPharma0.00%0.00%0.00%0.00%0.00%GNPXGENPREX+2.76%+10.61%-8.95%+9.16%-84.36%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%PRQRProQR Therapeutics+2.61%+10.13%+33.33%+110.71%+38.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AGNPXGENPREX1.1224 of 5 stars0.04.00.04.70.00.00.6NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics2.04 of 5 stars3.63.00.00.02.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTICCTI BioPharma 0.00N/AN/AN/AGNPXGENPREX 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/APRQRProQR Therapeutics 3.13Buy$8.00238.84% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, CTIC, PRQR, and NMTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.006/27/2025PRQRProQR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93GNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/APRQRProQR Therapeutics$20.46M12.14N/AN/A$0.91 per share2.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/AGNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/APRQRProQR Therapeutics-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)Latest GNPX, CTIC, PRQR, and NMTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025N/AGNPXGENPREX-$0.71N/AN/AN/AN/AN/A5/12/2025Q1 2025GNPXGENPREX-$0.82-$0.26+$0.56-$0.26N/AN/A5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTICCTI BioPharmaN/AN/AN/AN/AN/AGNPXGENPREXN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTICCTI BioPharmaN/A1.271.26GNPXGENPREXN/A1.941.94NMTR9 Meters BiopharmaN/A0.590.59PRQRProQR TherapeuticsN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTICCTI BioPharma91.45%GNPXGENPREX14.05%NMTR9 Meters Biopharma22.34%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipCTICCTI BioPharma7.61%GNPXGENPREX8.47%NMTR9 Meters Biopharma2.40%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableGNPXGENPREX2033.15 million30.34 millionNo DataNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataPRQRProQR Therapeutics180105.21 million96.38 millionOptionableGNPX, CTIC, PRQR, and NMTR HeadlinesRecent News About These CompaniesProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8 at 8:53 AM | investing.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's WhyJuly 8 at 4:56 AM | marketbeat.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMBrokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00July 3, 2025 | americanbankingnews.comPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from BrokeragesJune 30, 2025 | marketbeat.comProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comProQR Therapeutics N.V. (PRQR) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 27, 2025 | finanznachrichten.deProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP SecuritiesJune 27, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor FitzgeraldJune 27, 2025 | marketbeat.comProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 26, 2025 | globenewswire.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 2, 2025 | tipranks.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, CTIC, PRQR, and NMTR Company DescriptionsCTI BioPharma NASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.GENPREX NASDAQ:GNPX$0.28 -0.01 (-2.37%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.ProQR Therapeutics NASDAQ:PRQR$2.36 +0.00 (+0.04%) As of 10:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
